4Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial[J]. JAMA, 2002,288(3):321-333.
5Gallagher JC, Baylink DJ, Freeman R, et al. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized double-blind, placebo-controlled, dose-finding studies[J].J Clin Endocrinol Metab,2001,86(10):4717-4726.
6Fitzpatrick LD, Nachtigall LE. Low dose: a new era for hormone therapy[J]? Menopause Management,2004,13(1):54-56.
7Rossouw JE,Anderson GL,Prentice RL,et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the Women's Health Initiative randomized controlled trial.JAMA,2002,288 (3):321-333.
8Lindsay R,Gallagher JC,Kleerekoper M,et al.Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in acetate on bone in early postmenopausal women.JAMA,2002,287 (20):2668-2676.
9Delmas PD,Confavreux E,Garnero P,et al.A combination of low doses of 17β-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women.Osteoporosis Int,2000,11 (2):177-187.
10Lees B,Stevenson JC.The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol17 beta and dydrogesterone.Osteopotos Int,2001,12 (4):251-258.
